Recent News

• 02.14.2025 - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
• 02.13.2025 - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
• 01.23.2025 - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
• 01.15.2025 - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
• 01.07.2025 - InflaRx Announces Participation in January Events in San Francisco
• 12.20.2024 - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
• 11.15.2024 - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
• 11.08.2024 - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
• 11.08.2024 - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
• 10.31.2024 - InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

Recent Filings

• 02.13.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.15.2025 - EX-99.1 EX-99.1
• 01.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.20.2024 - EX-99.1 EX-99.1
• 12.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.15.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.08.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]